Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET AMPLIFICATION ( ENST00000318493.11 )
MET AMPLIFICATION ( ENST00000318493.11 )
Associated Disease
lung adenocarcinoma
Source Database
CIViC Evidence
Description
In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP. The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1692
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/270
Rating
3
Evidence Type
Predictive
Disease
Lung Adenocarcinoma
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
25922291
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue